Evidence map›Paper›PMID 39045171›Full record

ArticleImmuno-oncology technology2024

Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.

I A J van Duin, M Schuiveling, L S Ter Maat, M Veta, M J M van Eijs, R J Verheijden, F W P J van den Berkmortel, M J Boers-Sonderen, G A P Hospers, M Labots and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immuno-oncology technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

I A J van DuinDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht.
M SchuivelingDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht.
L S Ter MaatImage Sciences Institute, University Medical Center Utrecht, Utrecht University, Utrecht.
M VetaMedical Image Analysis, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven.
M J M van EijsDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht.
R J VerheijdenDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht.
F W P J van den BerkmortelDepartment of Medical Oncology, Zuyderland Medical Centre, Sittard-Geleen.
M J Boers-SonderenDepartment of Medical Oncology, Radboud University Medical Centre, Nijmegen.
G A P HospersDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen.
M LabotsDepartment of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam.
J W B de GrootIsala Oncology Center, Isala, Zwolle.
E KapiteijnDepartment of Medical Oncology, Leiden University Medical Centre, Leiden.
D PiersmaDepartment of Internal Medicine, Medisch Spectrum Twente, Enschede.
G VreugdenhilDepartment of Internal Medicine, Maxima Medical Centre, Eindhoven.
H WestgeestDepartment of Internal Medicine, Amphia Hospital, Breda.
A M R SchraderDepartment of Pathology, Leiden University Medical Centre, Leiden.
P J van DiestDepartment of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
W A M BlokxDepartment of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
K P M SuijkerbuijkDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The predictive value of tumor-infiltrating lymphocytes (TILs) in immune-related adverse event (irAE) development remains unknown, although an association between tumor immunogenicity and irAEs has been suggested. We investigated the association between TIL abundance in pretreatment primary and metastasis specimens and the subsequent development of severe irAEs. Patients and methods: We retrospectively identified patients with advanced cutaneous melanoma who received first-line anti-programmed cell death protein 1 (PD-1) with or without anti-cytotoxic T-lymphocyte associated protein 4 (anti-CTLA-4) from 10 hospitals in the Netherlands. TILs were scored on representative hematoxylin and eosin (H&E) stains of the primary melanoma and pretreatment melanoma metastasis as 'absent', 'nonbrisk', or 'brisk'. A univariable logistic regression analysis was carried out to assess the association between the TIL scores and the development of severe irAEs. Fine and Gray subdistribution hazard models were used to estimate the cumulative incidence of severe irAEs. Results: Of the 1346 eligible patients, 536 patients had primary melanoma specimens available, and 613 patients had metastasis specimens available. Severe irAEs occurred in 15% of anti-PD-1-treated patients and 49% of anti-PD-1 + anti-CTLA-4-treated patients. The presence of TILs was not associated with the occurrence of grade ≥3 irAEs in primary melanoma specimens ( Conclusion: There was no association between the TIL scores on H&E-stained slides from the primary melanoma or pretreatment metastasis and the development of grade 3 or higher irAEs. Additionally, no correlation was found between the presence of TILs and the timing of irAEs.

Indexed as

immune-related adverse eventsimmunotherapymelanomapathologytumor-infiltrating lymphocytes

Identifiers

PMID39045171
PMCPMC11262179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.